Lutetium (177Lu) Zadavotide guraxetan is a synthetic peptide commercialized by POINT Biopharma Global, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 4 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Lutetium (177Lu) Zadavotide guraxetan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Lutetium (177Lu) Zadavotide guraxetan is expected to reach an annual total of $59 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Lutetium (177Lu) Zadavotide guraxetan Overview

Lutetium (177Lu) zadavotide guraxetan (PNT-2002) is under development for the treatment of metastatic castration resistant prostate cancer and oligorecurrent prostate cancer. It is administered through intravenous route. The drug candidate consists of PSMA ligand conjugated with lutetium 177 and acts by targeting cells expressing PSMA. It is being developed based on canSEEK technology.

POINT Biopharma Global Overview

Point Biopharma Global (Point Biopharma), formerly Therapeutics Acquisition Corp, is a radiopharmaceutical company. It develops and commercializes radioligands for cancer. The company is investigating PNT2002 against mCRPC (metastatic castration resistant prostate cancer); PNT2003 program to treat neuroendocrine tumors; PNT2004 targeting solid tumors expressing FAP (fibroblast activation protein); and PNT2001 against prostrate cancer. It utilizes CanSEEK platform technology to develop cancer treatments. The company’s technology aims to minimize toxicity caused by off-target delivery by activating radiopharmaceuticals that target ligands. Point Biopharma is headquartered in Indianapolis, Indiana, the US.

The operating loss of the company was US$45.5 million in FY2021, compared to an operating loss of US$13.1 million in FY2020. The net loss of the company was US$45.9 million in FY2021, compared to a net loss of US$13.4 million in FY2020.

For a complete picture of Lutetium (177Lu) Zadavotide guraxetan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.